Conclusions: Everolimus regimen compared with EC-MPS regimen is associated with lower incidence of DGF, slightly better 1-year graft survival rate, a significantly higher GFR and lower systolic blood pressure.
PMID: 21240873 [PubMed - as supplied by publisher] (Source: Journal of Nephrology)